Advertisement

Topics

High Risk for Invasive Meningococcal Disease With Eculizumab

08:00 EDT 4 Aug 2017 | Medscape

This report details the increased risk for serious meningococcal disease in patients receiving eculizumab for treatment of paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome.
Morbidity & Mortality Weekly Report

Original Article: High Risk for Invasive Meningococcal Disease With Eculizumab

NEXT ARTICLE

More From BioPortfolio on "High Risk for Invasive Meningococcal Disease With Eculizumab"

Quick Search
Advertisement